Search Medical Condition
Please enter condition
Please choose location from dropdown

Fleury sur Orne, France Clinical Trials

A listing of Fleury sur Orne, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (400) clinical trials

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Four cycles of treatment are proposed at 28 day intervals in an ambulatory setting Cycle 1 : - Cytarabine 10 mg /m2/day subcutaneous injection for 14 days - Bortézomib 1,5mg/m2 days 1,4,8,11 Cycles 2, 3, 4 : - Cytarabine 20 mg /m2/j subcutaneous injections for 14 days - Bortézomib 1,5mg/m2 ...

Phase

2.36 miles

Learn More »

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Inclusion of MDS with IPSS low or int-1 and hemoglobin < 10/dL. Study drug: Darbepoetin alfa (Aranesp) 500 microg every two weeks subcutaneously during 12 weeks, combined to filgrastim 300 microg twice weekly for an additional 12 weeks in non responders. Response will be evaluated at 12 weeks. Patients with ...

Phase

2.36 miles

Learn More »

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

Purpose : The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of Gemtuzumab Ozogamicin (GO) in addition with standard doses of Ara-C in previously untreated patients aged 60 to 80 years with de novo acute myeloblastic ...

Phase

2.36 miles

Learn More »

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

French national multicentric phase III trial evaluating chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma

Phase

2.36 miles

Learn More »

Transcriptomes Breast Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer

This study requires two steps: The first part of the study will be conducted on a population of 20 women free of breast cancer and, or ovarian Family (healthy volunteers controls) and without a known family history of breast and or ovarian cancer. Mapping the level of blood (leukocytes) and ...

Phase N/A

2.36 miles

Learn More »

The French EsoGastricTumours Data Base

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.

Phase N/A

2.36 miles

Learn More »

Decompressive Hemicraniectomy in Intracerebral Hemorrhage

Background Spontaneous intracerebral hemorrhage (ICH) remains a devastating disease with mortality rates up to 52% at 30 days. It is a major public health problem with an annual incidence of 10-30 per 100'000 population, accounting for 2 million (10-15%) of about 15 million strokes worldwide each year. One-third of patients ...

Phase N/A

2.36 miles

Learn More »

EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin

Primary objective : To demonstrate that a daily weight-based low dose of rifampicin is non-inferior to a high dose in the treatment of susceptible Staphylococcus spp. osteo-articular infections. Secondary objectives : To compare, in the two treatment groups (weight-based low dose rifampicin versus weight-based high dose): Possible failure rates (when ...

Phase

2.36 miles

Learn More »

Treatment of Chronic Subdural Hematoma by Corticosteroids

The primary objective is to evaluate the efficacy of corticosteroids treatment in patients with Chronic subdural hematomas without clinical or radiological signs of severity. Secondary objectives are to assess the effect of methylprednisolone on: quality of life evolution, morbidity and mortality, radiological evolution of the lesions.

Phase

2.36 miles

Learn More »

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)

Patients will be randomised to continue on TKI (same daily dose) versus one of the alternative novel treatment approaches. If a patient is not eligible for one of the treatments, he can be randomised for the options for which he is eligible. All treatment options may be open at all ...

Phase

2.36 miles

Learn More »